Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
XRP Whales’ Sale of 160 Million (~$480M) May Signal Short-Term Weakness as Active Addresses Fall

XRP Whales’ Sale of 160 Million (~$480M) May Signal Short-Term Weakness as Active Addresses Fall

CoinotagCoinotag2025/09/15 10:48
By:Marisol Navaro

  • Whales sold 160M XRP (~$480M) in 14 days, triggering profit-taking.

  • XRP price slipped to $2.98, down 2.95% in 24 hours with volume falling 9.45% to $5.22B.

  • On-chain metrics show active XRP Ledger accounts plunged ~50%, reducing transactional demand.

Meta description: XRP price sees whale sell-off of 160M XRP (~$480M), active accounts drop ~50% and volume falls; read our on-chain analysis and key takeaways now.





What is driving the XRP price decline?

XRP price weakness is driven primarily by large holder profit-taking and falling on-chain activity. Whales dumped 160 million XRP over 14 days, and active XRP Ledger accounts fell nearly 50%, reducing transactional demand and prompting short-term consolidation pressure.

How many XRP did whales sell and what was the value?

Large holders sold 160 million XRP in the last 14 days, representing roughly $480 million at peak levels. Crypto analyst Ali Martinez reported the sell-off, which coincided with a brief breakout above $3 and immediate profit-taking by whales.

XRP technical signals align with weakness

Price action shows XRP briefly peaked at $3.09 before retreating. The altcoin failed to hold above the Bollinger Bands upper band near $3.14, indicating the rally lost momentum and short-term technical strength declined.

As of press time, XRP is trading at $2.98, a 2.95% drop over 24 hours. Trading volume slipped 9.45% to $5.22 billion, signaling reduced market participation after the spike above $3.

Why are on-chain metrics important for XRP’s outlook?

On-chain data helps confirm whether price moves are supported by real usage. Active accounts on the XRP Ledger reportedly fell by nearly 50%. That decline suggests transactional demand weakened, increasing the likelihood of consolidation rather than a sustained breakout.

How should traders interpret whale sell-offs?

Whale liquidations often cause short-term volatility. A large sell-off can indicate profit-taking and a pause in bullish momentum. Traders should combine on-chain signals with volume and volatility indicators to assess risk.

Expert context: Ali Martinez, a crypto analyst, highlighted the scale of these sales. Independent reporting and on-chain explorers (plain text references) corroborate the timing and size of the outflows.


Frequently Asked Questions

Did whale sales trigger XRP’s pullback?

Yes. The concentrated sale of 160 million XRP over two weeks prompted profit-taking, pushing price back below $3 and increasing short-term downside risk for the token.

Is the drop in active accounts a long-term concern?

A near 50% decline in active XRP Ledger accounts is concerning for demand. If activity remains low, it may hinder sustained price recovery in the near term.

Key Takeaways

  • Whale sell-off: 160M XRP (~$480M) sold in 14 days, prompting profit-taking.
  • Price and volume: XRP trading near $2.98, down 2.95% in 24h; volume down ~9.45% to $5.22B.
  • On-chain weakness: Active XRP Ledger accounts fell nearly 50%, reducing transactional support for a rally.

Conclusion

Short-term XRP price dynamics show clear signs of profit-taking and reduced on-chain demand. With whales offloading 160 million XRP and active accounts dropping sharply, the market faces consolidation risk. Monitor on-chain metrics, volume, and technical indicators for confirmation before assuming a sustained recovery. COINOTAG will continue tracking developments and updating this report.

In Case You Missed It: Bitcoin Near $115.7K May Be Poised for Further Gains as 76% of Supply Is Held Long-Term and NUPL Signals Optimism
1
1

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Wall Street Stands Guard as Bessent Strikes Again: Aftereffects of August's "Treasury Turnaround" Persist, November Refinancing Notice Could Be the Next Flashpoint

As the US Treasury prepares to update its debt management plan in November, key clues may emerge on Friday.

智通财经•2026/10/16 01:06

"Coca-Cola belief" never goes out of style! KFC in America says goodbye to Pepsi and embraces Coca-Cola (KO.US); Buffett-style "boring investment" returns to the spotlight

KFC has chosen Coca-Cola as its soda supplier in the United States, abandoning its long-term partner Pepsi. As of the close of the U.S. stock market on Thursday, Coca-Cola's (KO.US) stock price reached a record high, defying the ongoing declines in global tech stocks, especially in the semiconductor and broad AI computing sectors.

智通财经•2026/10/16 01:06

AI financing concerns weigh heavily on chip stocks, global tech sector has lost over $1 trillion this week

Multiple pressures, including rising expectations of a Federal Reserve rate hike and increasing AI financing costs, have led to a massive sell-off in global tech stocks this week. The combined market value of the world's top 20 AI and semiconductor stocks has evaporated by more than $1 trillion, and the semiconductor ETF (SOXX) has recorded its longest losing streak in 11 years. On Thursday, SK Hynix continued to plunge by over 10% in a single day, while Nvidia, Samsung, and SoftBank were not spared.

华尔街见闻•2026/10/16 00:51

Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs

Amid concerns over AI capital expenditures, funds are seeking a "certainty premium." State Street Healthcare ETF reached a record high. Eli Lilly and AbbVie are both approaching their historical highest closing prices, while Gilead and Amgen have surged 7.7% and 7.2% respectively over the past five days. Eli Lilly continues to bet on the future through its GLP-1 dominance and 40 M&A deals totaling $20 billion. AbbVie's core drug Skyrizi has shown positive data for its new subcutaneous formulation, which is expected to extend its patent and drive additional sales.

华尔街见闻•2026/10/16 00:37
Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs